Trials / Unknown
UnknownNCT05333588
The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme.
The Safety and Efficacy Study of Autologous Tumor-infiltrating Lymphocyte (TILs) Therapy Combined With Conventional Chemotherapy for Patients With Advanced Stage of Glioblastoma Multiforme.
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The study is to evaluate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy for patients with maligant glioblastoma multiforme. Autologous TiLs should be given by intravenous infusion after 5 days of lymphodepletion treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Tumor Infiltrating Lymphocytes (TIL) | The autologous TILs will be intravenous infused into patients. |
Timeline
- Start date
- 2022-02-15
- Primary completion
- 2024-02-15
- Completion
- 2025-02-15
- First posted
- 2022-04-19
- Last updated
- 2022-04-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05333588. Inclusion in this directory is not an endorsement.